Aurinia Pharmaceuticals
AUPH
191 hedge funds and large institutions have $498M invested in Aurinia Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 59 increasing their positions, 64 reducing their positions, and 26 closing their positions.
28% more call options, than puts
Call options by funds: $28.4M | Put options by funds: $22.1M
26% more capital invested
Capital invested by funds: $395M → $498M (+$103M)
3.15% more ownership
Funds ownership: 35.46% → 38.61% (+3.2%)
8% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 64
4% less funds holding
Funds holding: 198 → 191 (-7)
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$28.7M |
| 2 |
Morgan Stanley
New York
|
+$12.2M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$8.57M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.14M |
| 5 |
Goldman Sachs
New York
|
+$4.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$7.77M |
| 2 |
Renaissance Technologies
New York
|
-$4.35M |
| 3 |
Two Sigma Investments
New York
|
-$3.74M |
| 4 |
Two Sigma Advisers
New York
|
-$3.57M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$2.69M |
AUPH Hedge Fund Activity: Q4 2023 in Review
191 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2023, worth a combined $498M — up 26% from $395M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of AUPH and 22 opened new positions — a net loss of 4 holders — while 64 trimmed existing stakes and 59 added.
The largest buyer was Armistice Capital, adding an estimated $28.7M. The largest seller was Artal Group, exiting entirely with an estimated $7.77M sold.
- 191 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2023, down from 198 in Q3 2023.
- Funds reported $498M of Aurinia Pharmaceuticals stock for Q4 2023, up 26% quarter-over-quarter.
- 22 funds opened new Aurinia Pharmaceuticals positions in Q4 2023 and 26 closed out, a net change of -4 holders.
- The largest Aurinia Pharmaceuticals buyer in Q4 2023 was Armistice Capital, an estimated $28.7M added.
- The largest Aurinia Pharmaceuticals seller in Q4 2023 was Artal Group, an estimated $7.77M sold.
Based on aggregated 13F filings for Q4 2023.